Commission expands future vaccines portfolio with new talks

CureVac is the latest company ready to supply the EU

The European Commission has today concluded exploratory talks with CureVac to purchase a potential vaccine against Covid-19, the EU press service reported. This is following the positive steps with Sanofi-GSK on 31 July and Johnson & Johnson on 13 August and the signature of an Advance Purchase Agreement with AstraZeneca on 14 August.

The envisaged contract with CureVac would provide for the possibility for all Member States to purchase the vaccine, as well as to donate to lower and middle income countries or re-direct to European countries. It is anticipated that the Commission will have a contractual framework in place for the initial purchase of 225 million doses on behalf of all EU Member States, to be supplied once a vaccine has proven to be safe and effective against Covid-19. The Commission pursues intensive discussions with other vaccine manufacturers.

“The Commission delivers on its promise to secure rapid access for Europeans and the world to a safe vaccine that protects us against the coronavirus. Each round of talks that we conclude with the pharmaceutical industry brings us closer to beating this virus,“ EC President Ursula von der Leyen said. “We continue to work shoulder to shoulder with Member States and with vaccine developers to fulfil the aims of our European Vaccines Strategy - a vaccine for all,” Health Commissioner Stella Kyriakides added.

CureVac is a European company pioneering the development of a completely new class of vaccines based on messenger RNA (mRNA), transported into cells by lipid nanoparticles. The vaccine platform has been developed over the last decade. The basic principle is the use of this molecule as a data carrier for information, with the help of which the body itself can produce its own active substances to combat various diseases. On 6 July, the European Investment Bank and CureVac signed a €75m loan agreement for the development and large-scale production of vaccines, including CureVac's vaccine candidate against COVID-19.

The exploratory talks concluded today are intended to result in an Advance Purchase Agreement to be financed with the Emergency Support Instrument, which has funds dedicated to the creation of a portfolio of potential vaccines with different profiles and produced by different companies.

More on this subject: Coronavirus

Similar articles